BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 27372407)

  • 1. Co-delivery of IL17RB siRNA and doxorubicin by chitosan-based nanoparticles for enhanced anticancer efficacy in breast cancer cells.
    Alinejad V; Hossein Somi M; Baradaran B; Akbarzadeh P; Atyabi F; Kazerooni H; Samadi Kafil H; Aghebati Maleki L; Siah Mansouri H; Yousefi M
    Biomed Pharmacother; 2016 Oct; 83():229-240. PubMed ID: 27372407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chitosan nanoparticles as a dual drug/siRNA delivery system for treatment of colorectal cancer.
    Sadreddini S; Safaralizadeh R; Baradaran B; Aghebati-Maleki L; Hosseinpour-Feizi MA; Shanehbandi D; Jadidi-Niaragh F; Sadreddini S; Kafil HS; Younesi V; Yousefi M
    Immunol Lett; 2017 Jan; 181():79-86. PubMed ID: 27916629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of HMGA2 siRNA and doxorubicin dual delivery by chitosan nanoparticles on cytotoxicity and gene expression of HT-29 colorectal cancer cell line.
    Siahmansouri H; Somi MH; Babaloo Z; Baradaran B; Jadidi-Niaragh F; Atyabi F; Mohammadi H; Ahmadi M; Yousefi M
    J Pharm Pharmacol; 2016 Sep; 68(9):1119-30. PubMed ID: 27350211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SiRNA/DOX lodeded chitosan based nanoparticles: Development, Characterization and in vitro evaluation on A549 lung cancer cell line.
    Seifi-Najmi M; Hajivalili M; Safaralizadeh R; Sadreddini S; Esmaeili S; Razavi R; Ahmadi M; Mikaeili H; Baradaran B; Shams-Asenjan K; Yousefi M
    Cell Mol Biol (Noisy-le-grand); 2016 Sep; 62(11):87-94. PubMed ID: 27755958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.
    Deng X; Cao M; Zhang J; Hu K; Yin Z; Zhou Z; Xiao X; Yang Y; Sheng W; Wu Y; Zeng Y
    Biomaterials; 2014 May; 35(14):4333-44. PubMed ID: 24565525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pulmonary Codelivery of Doxorubicin and siRNA by pH-Sensitive Nanoparticles for Therapy of Metastatic Lung Cancer.
    Xu C; Wang P; Zhang J; Tian H; Park K; Chen X
    Small; 2015 Sep; 11(34):4321-33. PubMed ID: 26136261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-delivery of insulin-like growth factor 1 receptor specific siRNA and doxorubicin using chitosan-based nanoparticles enhanced anticancer efficacy in A549 lung cancer cell line.
    Shali H; Shabani M; Pourgholi F; Hajivalili M; Aghebati-Maleki L; Jadidi-Niaragh F; Baradaran B; Movassaghpour Akbari AA; Younesi V; Yousefi M
    Artif Cells Nanomed Biotechnol; 2018 Mar; 46(2):293-302. PubMed ID: 28362176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folate-decorated hydrophilic three-arm star-block terpolymer as a novel nanovehicle for targeted co-delivery of doxorubicin and Bcl-2 siRNA in breast cancer therapy.
    Qian J; Xu M; Suo A; Xu W; Liu T; Liu X; Yao Y; Wang H
    Acta Biomater; 2015 Mar; 15():102-16. PubMed ID: 25545322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of the codelivery of drug-siRNA by trimethyl chitosan nanoparticles on the efficacy of chemotherapy for metastatic breast cancer cell line (MDA-MB-231).
    Eivazy P; Atyabi F; Jadidi-Niaragh F; Aghebati Maleki L; Miahipour A; Abdolalizadeh J; Yousefi M
    Artif Cells Nanomed Biotechnol; 2017 Aug; 45(5):889-896. PubMed ID: 27188536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGF-modified mPEG-PLGA-PLL nanoparticle for delivering doxorubicin combined with Bcl-2 siRNA as a potential treatment strategy for lung cancer.
    Zhang X; Wang Q; Qin L; Fu H; Fang Y; Han B; Duan Y
    Drug Deliv; 2016 Oct; 23(8):2936-2945. PubMed ID: 26739487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Knockdown of antiapoptotic genes in breast cancer cells by siRNA loaded into hybrid nanoparticles.
    de Mello LJ; Souza GR; Winter E; Silva AH; Pittella F; Creczynski-Pasa TB
    Nanotechnology; 2017 Apr; 28(17):175101. PubMed ID: 28230534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-tumor effects in mice induced by survivin-targeted siRNA delivered through polysaccharide nanoparticles.
    Yang F; Huang W; Li Y; Liu S; Jin M; Wang Y; Jia L; Gao Z
    Biomaterials; 2013 Jul; 34(22):5689-99. PubMed ID: 23632321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chitosan (CMD)-mediated co-delivery of SN38 and Snail-specific siRNA as a useful anticancer approach against prostate cancer.
    Afkham A; Aghebati-Maleki L; Siahmansouri H; Sadreddini S; Ahmadi M; Dolati S; Afkham NM; Akbarzadeh P; Jadidi-Niaragh F; Younesi V; Yousefi M
    Pharmacol Rep; 2018 Jun; 70(3):418-425. PubMed ID: 29626645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficient delivery of Bcl-2-targeted siRNA using cationic polymer nanoparticles: downregulating mRNA expression level and sensitizing cancer cells to anticancer drug.
    Beh CW; Seow WY; Wang Y; Zhang Y; Ong ZY; Ee PL; Yang YY
    Biomacromolecules; 2009 Jan; 10(1):41-8. PubMed ID: 19072631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Doxorubicin and siRNA Codelivery via Chitosan-Coated pH-Responsive Mixed Micellar Polyplexes for Enhanced Cancer Therapy in Multidrug-Resistant Tumors.
    Butt AM; Amin MC; Katas H; Abdul Murad NA; Jamal R; Kesharwani P
    Mol Pharm; 2016 Dec; 13(12):4179-4190. PubMed ID: 27934479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of anti-HER2-targeted doxorubicin-core-shell chitosan nanoparticles for the treatment of human breast cancer.
    Naruphontjirakul P; Viravaidya-Pasuwat K
    Int J Nanomedicine; 2019; 14():4105-4121. PubMed ID: 31239670
    [No Abstract]   [Full Text] [Related]  

  • 17. Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles.
    Duan J; Mansour HM; Zhang Y; Deng X; Chen Y; Wang J; Pan Y; Zhao J
    Int J Pharm; 2012 Apr; 426(1-2):193-201. PubMed ID: 22274587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blockade of CD73 using siRNA loaded chitosan lactate nanoparticles functionalized with TAT-hyaluronate enhances doxorubicin mediated cytotoxicity in cancer cells both in vitro and in vivo.
    Salehi Khesht AM; Karpisheh V; Sahami Gilan P; Melnikova LA; Olegovna Zekiy A; Mohammadi M; Hojjat-Farsangi M; Majidi Zolbanin N; Mahmoodpoor A; Hassannia H; Aghebati-Maleki L; Jafari R; Jadidi-Niaragh F
    Int J Biol Macromol; 2021 Sep; 186():849-863. PubMed ID: 34245737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour-Targeted and Redox-Responsive Mesoporous Silica Nanoparticles for Controlled Release of Doxorubicin and an siRNA Against Metastatic Breast Cancer.
    Zhuang J; Chen S; Hu Y; Yang F; Huo Q; Xie N
    Int J Nanomedicine; 2021; 16():1961-1976. PubMed ID: 33727809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The synergistic effect of hierarchical assemblies of siRNA and chemotherapeutic drugs co-delivered into hepatic cancer cells.
    Cao N; Cheng D; Zou S; Ai H; Gao J; Shuai X
    Biomaterials; 2011 Mar; 32(8):2222-32. PubMed ID: 21186059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.